University of Leicester
Browse
European J of Heart Fail - 2023 - Hoef - Biomarker signature and pathophysiological pathways in patients with chronic heart.pdf (900.02 kB)

Biomarker signature and pathophysiological pathways in chronic heart failure patients with metabolic syndrome.

Download (900.02 kB)
journal contribution
posted on 2023-07-07, 10:16 authored by Camilla CS van der Hoef, Eva M Boorsma, Johanna E Emmens, Bart J van Essen, Marco Metra, Leong L Ng, Stefan D Anker, Kenneth Dickstein, Ify R Mordi, Adel Dihoum, Chim C Lang, Dirk J van Veldhuisen, Carolyn SP Lam, Adriaan A Voors

Aim

The comorbidities that collectively define metabolic syndrome are common in patients with heart failure. However, the role of metabolic syndrome in the pathophysiology of heart failure is not well understood. We therefore investigated the clinical and biomarker correlates of metabolic syndrome in patients with heart failure.

Methods

In 1103 patients with heart failure, we compared the biomarker expression using a panel of 363 biomarkers among patients with (n = 468[42%]) and without (n = 635[58%]) metabolic syndrome. Subsequently, a pathway overrepresentation analysis was performed to identify key biological pathways. Findings were validated in an independent cohort of 1433 patients with heart failure of whom 615 (43%) had metabolic syndrome. Metabolic syndrome was defined as the presence of ≥ three of five criteria, including central obesity, elevated serum triglycerides, reduced high-density lipoprotein cholesterol, insulin resistance and hypertension.

Results

The most significantly elevated biomarkers in patients with metabolic syndrome were leptin (log2 fold change 0.92,P = 5.85 × 10-21 ), fatty acid-binding protein 4 (log2 fold change 0.61,P = 1.21 × 10-11 ), interleukin-1 receptor antagonist (log2 fold change 0.47,P = 1.95 × 10-13 ), tumour necrosis factor receptor superfamily member 11a (log2 fold change 0.35,P = 4.16 × 10-9 ), and RET proto-oncogene (log2 fold change 0.31,P = 4.87 × 10-9 ). Network analysis identified 10 pathways in the index cohort and 6 in the validation cohort, all related to inflammation. The primary overlapping pathway in both the index and validation cohort was up-regulation of the natural killer cell-mediated cytotoxicity pathway.

Conclusion

Metabolic syndrome is highly prevalent in heart failure and is associated with biomarkers and pathways relating to obesity, lipid metabolism and immune responses underlying chronic inflammation. This article is protected by copyright. All rights reserved.

History

Citation

van der Hoef, C.C.S., Boorsma, E.M., Emmens, J.E., van Essen, B.J., Metra, M., Ng, L.L., Anker, S.D., Dickstein, K., Mordi, I.R., Dihoum, A., Lang, C.C., van Veldhuisen, D.J., Lam, C.S.P. and Voors, A.A. (2023), Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome. Eur J Heart Fail, 25: 163-173. https://doi.org/10.1002/ejhf.2760

Author affiliation

Department of Cardiovascular Sciences

Version

  • VoR (Version of Record)

Published in

European journal of Heart Failure

Volume

25

Pagination

163-173

Publisher

Wiley

issn

1388-9842

eissn

1879-0844

Acceptance date

2022-12-20

Copyright date

2022

Available date

2023-01-04

Spatial coverage

England

Language

eng

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC